2

HEART OF THE MATTER **Exercise in Heart Failure**

r. George Burch, one of the great leaders in cardiology in the mid-20th century, wrote in a 1954 monograph that "the patient

with moderate or severe congestive heart failure should be placed at bed rest immediately." As a result, many patients were kept in bed for many weeks. This was the considered recommendation of many cardiologists, who had at the time little else to offer to their patients.

In the half century that followed, we learned a great deal about exercise physiology and its role in rehabilitating pa-

tients after an acute myocardial infarction. It is now part of the standard care of such patients.

More recently, a large body of clinical data has emerged providing insight into the role of exercise in the patient with heart failure. These studies suggest that, contrary to previous concerns, exercise training may be safe and can lead to im-

It's time to consider making exercise therapy a

proved cardiac physiology. There is now

significant evidence that exercise training

improves exercise performance, increases

peak oxygen consumption, reduces both

muscle and systemic sympathetic activity,

and favorably modifies systemic and tissue

On the basis of these physiologic stud-

ies, several clinical trials were performed

in the past decade and reported clinical

benefits associated with exercise training

in heart failure. Although most of the

studies have been small, they tended to re-

inforce the safety and physiologic benefits

of exercise training. These studies were

designed to include a broad spectrum of

LETTERS

CARDIOLOGY NEWS and its supplements

regard to the topic discussed. Letters

may be edited for space and clarity.

Mail: Letters, CARDIOLOGY NEWS, 5635 Fishers Lane, Suite 6000,

E-mail: cardnews@elsevier.com

Rockville, MD 20852

Fax: 240-221-2541

should include your name and address. affiliation, and conflicts of interest in

Letters in response to articles in

inflammatory markers.

standard, reimbursable treatment for heart failure.



patients with varying degrees of heart failure, such as elderly patients, who are becoming an increasingly large part of the heart failure population.

As a result of the progress in this field, in 2002 the National Heart, Lung, and Blood Institute embarked on HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training). The trial, involving more than 2,300 patients with New York Heart Association class I-IV heart failure with ejection fractions of less than 35%, tested the relative morbidity and mortality bene-

fit of exercise training in those who also were receiving optimal medical therapy.

Patients were randomized to usual care or a supervised exercise program for a concentrated 3-month period of exercise 3 days a week for 4 months, followed by home exercise 5 days a week for 2 years (CARDIOLOGY NEWS, Dec. 2008, p. 24). Although the trial did not achieve sta-

tistical significance in its primary goal of decreasing all-cause mortality or all-cause hospitalization, it did demonstrate a significant 14% decrease in the disease-specific clinical outcome of cardiovascular mortality or heart failure hospitalization. This effect on outcome is similar to that achieved with angiotensin receptor blockade when added to de novo heart failure patients. In addition, the trial further supported the safety of exercise therapy

in heart failure.

Many institutions have cardiac rehabilitation programs that include patients with heart failure. In some programs, the therapy is paid for by a third party. In light of the outcomes of HF-ACTION, an important question arises as to whether this therapy, with an expense that might be similar to the cost of providing cardiac rehabilitation for acute myocardial infarction patients, should become part of our standard reimbursement for Medicare and all third parties as an intrinsic part of heart failure therapy. This will be an important issue at a time when the escalating cost of health care is under increasing scrutiny.

Nevertheless, the result of HF-ACTION provides an important additional modality of treatment for heart failure patients and answers the question regarding the safety of exercise. The HF-ACTION investigators will need to provide the information, and some guidance, as to which patients with heart failure can benefit the most from exercise therapy.

DR. GOLDSTEIN, medical editor of CARDIOLOGY NEWS, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, Detroit.

Cardiology News

President, IMNG Alan J. Imhoff

Editor in Chief Mary Jo M. Dales

Turner, Elizabeth Wood

Wachter

Mary Ann Moon

Wells, Jane Locastro

the physician's practice.

vear

Г

cardiologynews@elsevier.com

Publication Editor Catherine Hackett

Senior Editors Christina Chase, Kathryn

Henderson, Sally Koch Kubetin, Teresa Lassman, Mark S. Lesney, Jane Salodof

MacNeil, Catherine Cooper Nellist, Amy

Pfeiffer, Calvin Pierce, Terry Rudd, Robin

Associate Editors Lorinda Bullock, Jay C.

Cherniak, Richard Franki, Randall Frey, Renée Matthews, Denise Napoli, Leanne Sullivan

Reporters Chicago: Patrice Wendling; Denver:

Bruce Jancin; London: Jonathan Gardner;

Los Angeles: Betsy Bates; Miami: Damian

Sullivan; New England: Diana Mahoney;

New York: Mary Ellen Schneider, Nancy

Walsh; Orlando: Fran Lowry; Philadelphia: Mitchel L. Zoler; San Diego: Doug Brunk;

San Francisco: Sherry Boschert, Robert Finn; Southeast: Sharon Worcester; Washington:

Alicia Ault, Jeff Evans, Elizabeth Mechcatie, Heidi Splete, Miriam E. Tucker, Kerri

Copy Editors Chief: Felicia R. Black; Assistant

Chief: Carol Nicotera-Ward; Therese Borden,

Julia Duncan, Mimi Harrison, Virginia Ingram-

Editorial Offices 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, 877-524-9336,

CARDIOLOGY NEWS is an independent newspaper that provides the practicing specialist with timely

and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and

The ideas and opinions expressed in CARDIOLOGY NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not

assume responsibility for damages, loss, or claims of any kind arising from or related to

the information contained in this publication.

POSTMASTER Send changes of address (with old mailing label) to CARDIOLOGY NEWS

Circulation, 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960.

CARDIOLOGY NEWS (ISSN 1544-8800) is published CARDOLOGY I VEWS (1351X 1944-5000) IS particular monthly by Elsevier Inc., 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250. Subscription price is \$95.00 per

including any claims related to the

drugs, or services mentioned herein

Contributing Writers Christine Kilgore,

McNamara; Mid-Atlantic: Michele G.

Executive Editors Denise Fulton, Kathy Scarbeck

DeMott, Lori Buckner Farmer, Joyce Frieden, Keith Haglund, Gwendolyn B. Hall, Gina L.

Executive Director, Operations Jim Chicca Director, Production/Manufacturing Yvonne Evans

Production Manager Judi Sheffer Production Specialists Victor De la Cruz, Anthony Draper, Tracey Law, Rebecca Slebodnik

Information Technology Manager Doug Sullivan Senior Systems Administrator Lee J. Unger Systems Administrator/Application Support Peter Ayinde

Operations Assistant Melissa Kasimatis Creative Director Louise A. Koenig Design Supervisor Elizabeth Byrne Lobdell Senior Designers Sarah L. Gallant, Julie Keller Design Staff Yenling Liu, Lisa M. Marfori Photo Editors Rebecca Gardner, Vivian E, Lee Project Manager Susan D. Hite Assignments Manager Megan Evans Department Coordinator Vicki Long Accounts Payable Coordinator Daniela Silva

V.P., Med. Ed./Bus. Development Sylvia H. Reitman

Program Manager, Med. Ed. Malika Wicks Senior Director, Marketing/Research Janice Theobald

Circulation Analyst Barbara Cavallaro, 973-290-8253, bcavallaro@elsevier.com Marketing Associate Jennifer Savo

Director of Sales Mark E. Altier, 973-290-8220, m.altier@elsevier.com

Sales Director, IMNG Phil Soufleris, 973-290-8224, p.soufleris@elsevier.com

National Account Manager Christy Tetterton, 973-290-8231. c.tetterton@elsevier.com

Business Controller Dennis Quirk

Adv. Services Manager Joan Friedman Credit Supervisor Patricia H. Ramsey

Manager, Administration/Conventions Lynne Kalish

Sales Assistant Karen Benarzi

Receptionist Linda Wilson

Advertising Offices 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250

Classified Sales Manager Brian Vishnupad, 212-633-3129,

fax 212-633-3820, b.vishnupad@elsevier.com Classified Advertising Offices 360 Park Ave.

South, 9th flr. New York, NY 10010, 212-462-1950

Address Changes Fax change of address (with old mailing label) to 973-290-8245 or e-mail change to subs@elsevier.com

Reprints Call 240-221-2419

©Copyright 2009, by Elsevier Inc.



VITAL SIGNS

10 Most Expensive Conditions Treated in Hospitals (total national bill in billions of dollars)

Coronary artery disease	
Pregnancy and delivery	
Newborn infants	\$3
Acute myocardial infarction	\$35.
Heart failure	\$32.8
Sepsis	\$30.3
Osteoarthritis	\$28.0
Pneumonia	\$27.5
Device/implant/graft complication	\$27.4
Respiratory failure (adult)	\$23.7

e products,

\$52.6

\$47.8

38.2

.1

Note: Based on data from the 2006 Nationwide Patient Sample. Source: Agency for Healthcare Research and Quality